Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Recurrence × encorafenib × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Melanoma 28 Colorectal Neoplasms 21 Colonic Neoplasms 7 Carcinoma, Non-Small-Cell Lung 7 Brain Neoplasms 7 Neoplasms 6 Neoplasm Metastasis 5 Skin Neoplasms 3 Rectal Neoplasms 3 Lung Neoplasms 3 Gastrointestinal Neoplasms 3 Pancreatic Neoplasms 2 Digestive System Neoplasms 2 Thyroid Neoplasms 1 Solid Tumors Harboring a BRAF V600 Mutation 1 Solid Tumors 1 Skin Diseases 1 Recurrence 1 Rectal Diseases 1 Neurofibromatosis 1 1 Multiple Myeloma 1 Lymphatic Metastasis 1 Leukemia, Hairy Cell 1 Intestinal Neoplasms 1 Intestinal Diseases 1 Hereditary Sensory and Autonomic Neuropathies 1 Hematologic Neoplasms 1 Gliosarcoma 1 Glioma 1 Glioblastoma 1

Interventions

Cyclophosphamide 133 Dexamethasone 107 Rituximab 70 fludarabine 65 Lenalidomide 59 Cytarabine 59 Gemcitabine 54 fludarabine phosphate 49 Bortezomib 48 pembrolizumab 46 venetoclax 45 Etoposide 44 Paclitaxel 43 Carboplatin 42 Cisplatin 41 pomalidomide 39 Peripheral Blood Stem Cell Transplantation 38 Filgrastim 37 Radiotherapy 35 Bevacizumab 33 Melphalan 31 Busulfan 31 Calcium Dobesilate 29 carfilzomib 28 Cyclosporine 28 Methotrexate 27 Azacitidine 26 Nivolumab 25 Mycophenolic Acid 25 Temozolomide 24

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02834364 2023-11-24

GMMG-BIRMA

University of Heidelberg Medical Center

Phase 2 Completed

Multiple Myeloma, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon ⚡